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Abstract
Background: Most comparisons of robot‐assisted (RARC) versus open radical cys-
tectomy (ORC) for urothelial carcinoma do not factor the inherent stage selection
bias or surgical experience.
Methods: We compared the perioperative outcomes of 229 RARC and 335 ORC at
a single tertiary referral centre with propensity score matching and multiple
regression models, when controlling for tumour and patient characteristics, sur-
geon's experience and type of urinary diversion.
Results: RARC had less major complications (19.8% vs. 34.1%) and ICU admissions
(6.6% vs. 19.8%), with lower blood loss (400 vs. 500 ml) and transfusion rates. The
operating time was longer (336 vs. 286 min), but decreased with surgeon's expe-
rience. RARC had less positive surgical margins (3% vs. 8.4%) and a higher lymph
node count (14 vs. 11).
Conclusions: In this large single centre series comparing RARC with ORC control-
ling for stage selection bias and surgical experience, RARC proved significantly
better outcomes, especially with intracorporeal urinary diversion.
K E YWORD S
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1 | INTRODUCTION
Since the first robot‐assisted radical cystectomy (RARC) in 2003,
RARC has been increasingly performed and is now considered a
standard surgical approach besides open radical cystectomy (ORC)
for the treatment of muscle‐invasive bladder cancer.1–3 However, the
gold standard for radical cystectomy is still a matter of controversial
debate, and RARC has not fully replaced the open approach, even in
experienced centres.3,4
Like other interventions, the outcomes of RARC are influenced by
a learning curve. According to the International Robotic Cystectomy
Consortium (IRCC), acceptable results can be achieved after 30 cases
for all urinary diversions, whereas an ongoing decrease of complica-
tions has recently been illustrated even after 60 intracorporeal urinary
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diversions (ICUD).5,6 However, RARC is no everyday intervention,
which explains why the learning curve is long.7
Another factor contributing to the deferred transition from the
open to the robotic approach were reports on atypical metastases
after RARC, which peaked in 2016.8–10 The reasons for this phe-
nomenon have not yet been fully understood, but meta‐analyses
recently indicated that the risk for atypical metastases is low after
RARC and decreases with growing surgical expertise.11–14
These aspects have led to a significant stage selection bias in
most analyses comparing RARC and ORC. Not only in our centre,
locally advanced tumours (≥cT3, cN+) have been preferably treated
with ORC in recent years. Currently, only five randomised controlled
trials (RCTs) have compared both surgical approaches and could not
demonstrate a significant superiority of RARC in terms of oncologic
or perioperative outcomes.13,15–18 In contrast, retrospective studies,
including meta‐analyses, found a lower blood loss and less compli-
cations or shorter hospital stays for RARC.19,20
For this reason, we performed a longitudinal single centre com-
parison of more than 550 RARC and ORC to analyse the perioper-
ative outcomes in one of the largest monocentric cohorts so far. For
the first time, we aimed to control not only for differences in patient
and tumour characteristics, but also for surgeon experience and the
type of urinary diversion. The impact of the surgical approach, pa-
tient‐ and tumour‐specific factors on outcomes, including complica-
tions and intensive care unit (ICU) admissions were compared.
2 | MATERIALS AND METHODS
In a retrospective cohort study, all consecutive ORC and RARC in
adults performed for urothelial carcinoma at a tertiary referral centre
between 2007 and 2019 were analysed, starting with the initiation of
a robotic program for RARC. Data acquisition was performed by
reviewing the individual medical records. The robotic surgeons were
consultants and experienced in all other urologic robotic in-
terventions, including at least 50–100 radical prostatectomies, (par-
tial) nephrectomies or pyeloplasties.21,22 They performed RARC as
previously described.23 Neobladders were performed in the ‘W’‐
shaped technique by Hautmann, irrespective of the surgical
approach.24 After radical cystectomy (RC), all patients were admitted
to an intermediate care unit by default, and only in the case of severe
complications were they admitted to the ICU.
The patient’s age, gender, body mass index (BMI) and Charlson
Comorbidity Index (CCI) served as patient‐related factors. The type
of urinary diversion, blood loss, total operating time (including the
docking process for RARC), conversions and intraoperative compli-
cations were obtained. The intraoperative complications were graded
according to the European Association of Urology intraoperative
adverse incident classification (EAUiaiC).25 The experience of a sur-
geon was defined as the current number of radical cystectomies he or
she performed. A robotic surgeon was considered as ‘experienced’ if
he or she had conducted more than 30 RARC, as proposed by the
IRCC, and the same threshold was applied for all ORC accordingly.5
The pathologic results were reviewed, including positive surgical
margins (PSMs) and the total lymph node yield. ICU admissions and
complications according to Clavien Dindo within 30 days after sur-
gery (major complications defined as ≥grade 3) served as primary
outcomes. As secondary outcomes, the operating time, blood loss,
number of blood transfusions, rate of PSMs, total lymph node count
and length of stay were analysed.
First, an overall comparison was performed between ORC and
RARC. In a separate subgroup analysis, all robotic extracorporeal
urinary diversions (ECUD) were compared with ICUD. To assess the
impact of the urinary diversion on perioperative outcomes, all pa-
tients with either ileal conduits or neobladders were compared be-
tween ORC, RARC with ICUD and RARC with ECUD in two separate
subgroup analyses, too. Next, a propensity score matching was con-
ducted for the surgeon’s experience (binary: experienced vs. not
experienced), type of urinary diversion (ileal conduit, neobladder vs.
other), pT‐ (≤T1, T2, T3 vs. T4) and pN‐stage (N0/Nx, N1 vs. N2) as
categorical variables and patient age and CCI as continuous variables
(Figure 1). The tolerance rate was set to 0.05 and the matched pairs
were compared again between ORC and RARC. To compare the
impact of the surgical approach, type of urinary diversion, surgeon’s
experience, patient age (per 10 years), gender, BMI, CCI (over vs.
under median), tumour stage (≤pT2 vs. >pT2) and lymph node me-
tastases (pN+ vs. pN0/X) on outcomes, univariate and multiple linear
and logistic regression analyses were conducted in the overall cohort.
Independent variables were only included in the multiple regression
analysis if the respective effect was significant in the univariate
analysis. For multiple regression analyses, forward selection was
applied.
Categorical variables were reported as frequencies and pro-
portions, continuous data as the median and range. Fisher’s exact,
Mann–Whitney U, Kruskal Wallis, McNemar and Wilcoxon rank‐sum
tests were applied. The statistical analyses were performed with
SPSS version 25 (IBM, Armonk, USA). All tests were two‐sided, p‐
values < 0.05 were considered significant. In the event of missing
data, cases were excluded. This study was approved by the respon-
sible ethical review board (Bu 181/11, 141/14); all patients provided
written informed consent. This analysis has been conducted in
adherence with the Helsinki Declaration and the STROBE guidelines
(checklist in Supplement).
3 | RESULTS
3.1 | Overall comparison
In total, 564 radical cystectomies (229 RARC and 335 ORC) were
included from 2007 to 2019. The median annual caseload did not
significantly differ between the groups (20 RARC/year vs. 29 ORC/
year) and increased from 10 in 2007 to 31 in 2013 for RARC
(Figure 2). All RARC were conducted by five surgeons with a median
experience of 28 interventions (range 2–92). All of them performed
ORC, which was also conducted by 13 other surgeons.
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Patients in the RARC group were younger (68 vs. 73 years) and
had a lower CCI (3 vs. 5.5, both p < 0.001, Table 1). They had lower
pT‐stages (pT4 9.2% vs. 17.3%) and less lymph node metastases (pN+
17.8% vs. 34.9%, both p < 0.01). In total, 74 (32.3%) RARC were
followed by ICUD, which were predominantly performed after 2013
(Figure 2). Ileal conduits were the most common urinary diversion in
both groups (RARC 70.7%, ORC 86.3%, Table 1).
Concerning the primary outcomes, RARC had less overall and
major complications (major 21% vs. 32.8%,p= 0.002, Table 2) as well as
intraoperative complications (13.1% vs. 19.4%, p= 0.041). Eight (3.5%)
RARC had to be converted, in two cases due to significant obesity and
the impossibility to inflate the abdomen and in two other cases because
of the suspicion of peritoneal carcinosis. In one case, a bleeding from
the periurethral plexus could not be controlled robotically and one
lesion in the ileum had to be sutured in an open fashion at the beginning
of the learning curve. One patient with significant abdominal adhesions
required open division, while the rest of the procedure was performed
with robotic assistance. One patient had a pelvic kidney with significant
anatomical variations. While grade 3 intraoperative complications only
occurred after ORC (2.7% vs. 0%, p = 0.012), there was one grade 5
complication during RARC (intraoperative death due to cardiac arrest
in the absence of major bleeding, Table S1). ICU admissions were
almost three times more frequent after ORC (7.4% vs. 20.3%,
p < 0.001). As for the secondary outcomes, blood loss (400 vs. 600 ml)
and transfusion rates were lower for RARC and the length of stay was
shorter (16 vs. 17 days, for all p < 0.001). The PSM rate was lower for
RARC (2.2% vs. 10.4%) and the total lymph node yield higher (15 vs. 12,
both p < 0.001). In contrast, the operating time was shorter for ORC
(377 vs. 270 min, p < 0.001).
3.2 | Subgroup analyses
When comparing only robotic ICUD with ECUD, patients in the ICUD
group were significantly older (69 vs. 66 years) and had a higher CCI (4
vs. 3, both p < 0.05, Table S2). The robotic surgeons performing ICUD
were more experienced than for ECUD (median experience for ICUD:
52.5 RARC vs. ECUD: 20 RARC, p < 0.001). There were no significant
differences regarding the perioperative outcomes, except for blood
loss which was significantly lower for ICUD (300 vs. 400 ml, p = 0.01).
When analysing patients with ileal conduits, only 289 patients
treated with ORC were significantly older (74 vs. 70 years) and had a
higher CCI than 110 patients treated with ECUD (5 vs. 3, for both
p < 0.001, Table 3). There were no differences compared to 52 pa-
tients with ICUD. Patients in both robotic groups had tumours with
lower pT and pN stages compared to ORC (for all, p < 0.05). A total of
78.8% robotic intracorporeal ileal conduits were performed by
experienced surgeons, in contrast to 30.9% extracorporeal and
50.2% open ileal conduits (for both p < 0.001). Both approaches for
robotic ileal conduits had better perioperative outcomes compared
to ORC with lower postoperative complications, ICU admissions,
lower blood loss, transfusion rates, PSMs and a shorter length of stay
(for all p < 0.01). However, intracorporeal robotic ileal conduits had
better perioperative outcomes than extracorporeal robotic ileal
conduits with a shorter operating time (332.5 vs. 356.5 min,
p = 0.035), less blood loss (200 vs. 400 ml, p < 0.001) and a higher
lymph node count (16.5 vs. 14, p = 0.018, Table 3).
Twenty‐one patients received robotic intracorporeal neo-
bladders, 44 robotic extracorporeal neobladders and 32 open neo-
bladders after ORC (Table S3). Patients in the ICUD group were older
compared to ECUD (61 vs. 54 years, p = 0.004). A total of 100% of
robotic intracorporeal neobladders were performed by experienced
surgeons, in contrast to 77.3% robotic extracorporeal and 46.9%
open neobladders after ORC (for both p < 0.001). None of the
perioperative outcomes significantly differed, except for the oper-
ating time, which was significantly longer with ICUD and ECUD
compared to ORC (429 vs. 441.5 vs. 312 min respectively, p < 0.001).
3.3 | Propensity score matched analysis
After propensity score matching, 167 matched pairs of ORC and
RARC did no longer differ concerning patient or tumour character-
istics, diversion types and surgeon’s experience (Table 4). All
F I GUR E 1 As the open and robotic cohorts differed in age, CCI,
diversion type, pT‐ and pN‐stage, a propensity score matching was
conducted to improve the comparability of 167 matched case‐
controls
F I GUR E 2 Annual caseload of open (bold line) and robot‐
assisted radical cystectomies (RARC), divided into intra‐ (dashed
line, ICUD) and extracorporeal urinary diversions (dotted line,
ECUD), between 2007 and 2019
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differences in primary and secondary outcomes remained significant
between the groups, except for the intraoperative complication rate,
which was still lower for RARC, but no longer statistically significant
(RARC 10.8% vs. 18.6%, p = 0.067).
3.4 | Multiple regression analysis
The surgical approach was the only factor which had a significant
impact on all primary outcomes in the multiple regression analysis
(Table 5). The robotic approach had a lower risk for intraoperative
complications (OR 0.41, 95% confidence interval (CI) 0.28–0.59),
postoperative minor (OR 0.52, 95%CI 0.34; 0.79) and major compli-
cations (OR 0.38, 95%CI 0.23; 0.61) and ICU admissions (OR 0.32,
95%CI 0.15; 0.55, all p < 0.01, Table 5). Older patients had a higher
OR for minor complications (OR 1.25 per 10 years, 95%CI 1.03; 1.53,
p = 0.028) in the multiple analysis.
All of the secondary outcomes were impacted by the surgical
approach too (Table S4). The blood loss was lower for RARC (B‐value
‐315.6 ml, 95%CI ‐179; ‐453, p < 0.001). Correspondingly, RARC had
a lower OR for blood transfusions (OR 0.23, 95%CI 0.15; 0.35,
p < 0.001). The OR for blood transfusions was also impacted by the
type of urinary diversion and was lower for neobladders (OR 0.52,
95%CI 0.27; 0.99), increased with patient age (per 10 years: OR 1.33,
95%CI 1.08; 1.64) and was higher for women (OR 1.61, 95%CI 1.08;
2.55, all p < 0.05). The operating time was influenced by five different
factors in the multiple analysis and was longer for RARC, neobladders
and patients with an increasing BMI, but was shorter for experienced
surgeons and older patients. PSMs were less likely after RARC (OR
0.27, 95%CI 0.1; 0.71), but more common with experienced surgeons
(OR 3.06, 95%CI 1.48; 6.34, both p < 0.01) and advanced tumours
(OR 14.4, 95%CI 4.3; 47.7, p < 0.001). The lymph node count was
higher for RARC (B‐value 3, 95%CI 1.4; 4.5), but lower with
increasing patient age (per 10 years ‐1.1, 95%CI ‐1.8; ‐0.4, both
p < 0.01). The length of stay was shorter for RARC (B‐value ‐4.3, 95%
CI ‐1.7; ‐6.9), longer for neobladders and other urinary diversions,
and increased with BMI (B‐value 0.56, 95%CI 0.3; 0.81, both
p = 0.001).
TAB L E 1 Patient and tumour
characteristics, urinary diversions and
surgeon’s experience within the study
cohort consisting of 564 RARC and ORC
RARC (n = 229) ORC (n = 335) p‐value
Patient characteristics
Age (yr) 68 (27; 88) 73 (30; 101) <0.001
Gender male 191 (83.4%) 260 (77.6%) 0.091
BMI (kg/m2) 26.4 (16.3; 41.7) 27.1 (18.3; 49.6) 0.360
CCI 3 (0; 11) 5.5 (0; 15) <0.001
Urinary diversion
Intracorporeal diversion 74 (32.3%) n.a.
Diversion type <0.001
Ileal conduit 162 (70.7%) 289 (86.3%) <0.001
Neobladder 65 (28.4%) 32 (9.6%) <0.001
Other 2 (0.8%) 14 (4.2%) 0.02
Tumour characteristics
pT <0.001
≤pT1 77 (33.6%) 60 (17.9%) <0.001
pT2 67 (29.3%) 88 (26.3%) 0.435
pT3 64 (27.9%) 129 (38.5%) 0.009
pT4 21 (9.2%) 58 (17.3%) 0.006
pN <0.001
N1 23 (10%) 44 (13.1%) 0.265
N2+ 18 (7.8%) 72 (21.8%) <0.001
Surgeon
Experienced surgeon 107 (46.7%) 169 (50.4%) 0.392
Note: Absolute numbers are given as median (range), proportions as absolute and relative
frequencies.
Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; n.a., not applicable; ORC,
open radical cystectomy; RARC, robot‐assisted radical cystectomy.
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4 | DISCUSSION
Within this study, 564 consecutive radical cystectomies (229 RARC
and 335 ORC) performed for urothelial carcinoma at one tertiary
referral centre from 2007 to 2019 were included. During this period,
the proportion of RARC increased from 24.4% in 2007 to 80% in
2012, but was then limited to less than 10 per year. This decrease
was caused by reports on early recurrences and atypical metastases
after RARC, which might have affected the oncological outcome.
Therefore, we narrowed our indication and performed RARC only in
patients with organ‐confined disease from 2016.8,9 Recently, the risk
for atypical metastases has proven to be low in several studies,
including the 5‐ and 10‐years oncological outcomes of the IRCC
which also comprised many of our RARC.12,26 Of great importance,
the oncological outcomes are comparable to ORC irrespective of the
urinary diversion, including orthotopic intracorporeal neo-
bladders.3,11,12,18,27 For this reason, we have broadened our indica-
tion for RARC again. However, even two robotic systems cannot
cover the high demand for robotic surgery, wherefore we cannot
offer RARC to all patients. Overall, we found RARC to have a lower
morbidity with less complications and ICU admissions, regardless of
the type of urinary diversion and surgical experience. Moreover,
RARC was superior in terms of all other secondary outcomes,
including PSMs or lymph node count, except for the operating time,
which was longer.
As primary outcome, the complication rates of our series are
comparable with those of others.28 In total, the major (RARC 21% vs.
32.8%) and overall (RARC 59% vs. 77.9%) postoperative complication
rates clearly favoured RARC. To date, five RCTs have prospectively
compared RARC and ORC and two had complication rates as the
primary outcome.29,30 In contrast to our results, both RCTs did not
find significant differences between the two surgical approaches, just
like the recent Cochrane meta‐analysis which summarised all five
RCTs.31 However, the CORAL trial only compared 20 ORC with 20
RARC and 20 laparoscopic RCs (LRC) with extracorporeal urinary
diversions. The power calculation estimated a 10%–15% complica-
tion rate for RARC with a true result of 55%, wherefore the authors
state that the sample size had been too small to derive definite
conclusions.30 Bochner et al. compared 60 RARC with 58 ORC in the
intent‐to‐treat analysis, but neither included intracorporeal urinary
diversions. In contrast to the RCTs, the large meta‐analysis of Novara
et al. described lower overall and major complications after RARC,
which is in line with our findings.20 This could result from the inclu-
sion of intracorporeal diversions, which can have a lower risk for
complications than ECUD according to the IRCC.32 Some authors
even state that RARC with an extracorporeal diversion does not have
TAB L E 2 Primary and secondary
outcomes in overall cohort
RARC (n = 229) ORC (n = 335) p‐value
Primary outcome
Intraoperative complications 30 (13.1%) 65 (19.4%) 0.043
Grade 1 (EAUiaiC) 12 (5.2%) 25 (7.5%) 0.295
Grade 2 17 (7.4%) 31 (9.3%) 0.444
Grade 3 ‐ 9 (2.7%) 0.012
Grade 4 ‐ ‐ 1.000
Grade 5 1 (0.4%) ‐ 0.226
Postoperative complications 135 (59%) 261 (77.9%) <0.001
Minor (Clavien Dindo 1, 2) 87 (38%) 150 (44.8%) 0.094
Major (Clavien Dindo ≥3) 48 (21%) 110 (32.8%) 0.002
ICU admission rate 17 (7.4%) 68 (20.3%) <0.001
Secondary outcome
Operating time (min) 377 (198; 774) 270 (70; 874) <0.001
Blood loss (ml) 400 (20; 2500) 600 (50; 6500) <0.001
Transfusion rate 48 (21%) 200 (59.7%) <0.001
Lymph node count 15 (0; 35) 12 (0; 52) <0.001
PSM 5 (2.2%) 35 (10.4%) <0.001
Length of stay (d) 16 (8; 96) 17 (7; 185) <0.001
Note: Absolute numbers are given as median (range), proportions as absolute and relative
frequencies.
Abbreviations: EAUiaiC, European Association of Urology intraoperative adverse incident
classification; ICU, intensive care unit; n.a., not applicable; ORC, open radical cystectomy; PSM,
positive surgical margin; RARC, robot‐assisted radical cystectomy.
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TAB L E 3 Subgroup analysis of patients with ileal conduits only













Age (yr) 71 (48; 87) 70 (27; 88) 0.182 74 (36; 90) 0.244 <0.001
Gender male 42 (80.8%) 90 (81.8%) 0.873 226 (78.2%) 0.678 0.426
BMI (kg/m2) 26.5 (16.3; 41.7) 27.0 (17.3; 40.1) 0.788 27.3 (18.4; 49.6) 0.905 0.546
CCI 4 (2; 11) 3 (2; 10) <0.001 5 (0; 15) 0.255 <0.001
Tumour characteristics
pT 0.722 0.010 0.018
≤pT1 16 (30.8%) 31 (28.2%) 0.560 47 (16.3%) 0.007 0.011
pT2 18 (34.6%) 32 (29.1%) 0.477 77 (26.6%) 0.238 0.624
pT3 15 (28.8%) 36 (32.7%) 0.620 113 (39.1%) 0.160 0.240
pT4 3 (5.8%) 11 (10.0%) 0.371 52 (18.0%) 0.027 0.050
pN 0.263 0.005 0.019
N1 5 (9.6%) 10 (9.1%) 0.914 37 (12.8%) 0.520 0.304








7 (13.5%) 15 (13.6%) 0.976 57 (19.7%) 0.287 0.158
Postoperative
complications




20 (38.5%) 46 (41.8%) 0.685 132 (45.7%) 0.335 0.489
Major (Clavien
Dindo ≥3)
7 (13.5%) 20 (18.2%) 0.452 95 (32.9%) 0.005 0.004




332.5 (198; 523) 356.5 (203; 618) 0.035 267 (125; 874) <0.001 <0.001
Blood loss (ml) 200 (50; 1000) 400 (20; 2000) <0.001 600 (50; 6500) <0.001 <0.001
Transfusion rate 7 (13.5%) 30 (27.3%) 0.051 180 (62.3%) <0.001 <0.001
Lymph node count 16.5 (0; 35) 14 (0; 29) 0.018 12 (0; 52) 0.002 0.073
PSM 1 (1.9%) 3 (2.75%) 0.759 31 (10.7%) 0.045 0.011
Length of stay (d) 14.5 (8; 68) 14.5 (8; 46) 0.655 16 (7; 99) <0.001 <0.001
Note: The results are compared between robotic intracorporeal and extracorporeal conduits, but also between intracorporeal versus open and
extracorporeal versus open ileal conduits. The corresponding p‐values are given and absolute numbers as median (range), proportions as absolute and
relative frequencies.
Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; ICU, intensive care unit; n.a., not applicable; ORC, open radical cystectomy;
PSM, positive surgical margin.
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any benefit over ORC at all.33 We are therefore very pleased that our
longitudinal analysis not only included 155 (67.7%) RARC as ECUD,
but also 74 (32.3%) as ICUD. The first ICUD was conducted in 2014
and continued to be maintained afterwards. In comparison with
ECUD, the complication rates were not statistically different, but had
a tendency to be lower for ICUD. However, when including patients
TAB L E 4 Comparison of propensity
score matched groups regarding primary
and secondary outcomes
RARC (n = 167) ORC (n = 167) p‐value
Patient characteristics
Age (yr) 70 (27; 88) 71 (36; 90) 0.582
Gender male 138 (82.76%) 137 (82%) 1.0
BMI (kg/m2) 26.2 (16.3; 41.7) 27.5 (18.3; 49.6) 0.218
CCI 3 (2; 11) 4 (0; 12) 0.436
Urinary diversion
Intracorporeal diversion 45 (26.9%) n.a. ‐
Diversion type 0.580
Ileal conduit 132 (79%) 139 (83.2%) 0.360
Neobladder 23 (20.4%) 24 (14.4%) 0.175
Other 1 (0.6%) 4 (2.4%) 0.375
Tumour characteristics
pT 0.642
≤pT1 46 (27.5%) 43 (25.7%) 0.680
pT2 51 (30.5%) 52 (31.1%) 0.903
pT3 52 (31.1%) 49 (29.3%) 0.714
pT4 18 (10.8%) 23 (13.8%) 0.423
pN 0.938
N1 19 (11.4%) 16 (9.6%) 0.710
N2+ 18 (10.8%) 20 (12%) 0.850
Surgeon
Experienced surgeon 66 (39.5%) 77 (46.1%) 0.267
Primary outcome
Intraoperative complications 18 (10.8%) 31 (18.6%) 0.067
Postoperative complications 98 (58.7%) 129 (77.2%) 0.001
Minor (Clavien Dindo 1, 2) 65 (38.9%) 72 (43.1%) 0.525
Major (Clavien Dindo ≥3) 33 (19.8%) 57 (34.1%) 0.006
ICU admission rate 11 (6.6%) 33 (19.8%) 0.001
Secondary outcome
Operating time (min) 336 (198; 618) 286 (125; 874) <0.001
Blood loss (ml) 400 (20; 2500) 500 (150; 6500) 0.007
Transfusion rate 36 (21.6%) 101 (60.5%) <0.001
Lymph node count 14 (0; 35) 11 (0; 52) <0.001
PSM 5 (3%) 14 (8.4%) <0.001
Length of stay (d) 15 (8; 96) 17 (7; 185) 0.002
Note: Absolute numbers are given as median (range), proportions as absolute and relative
frequencies.
Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; ICU, intensive care unit; n.a.,
not applicable; ORC, open radical cystectomy; PSM, positive surgical margin; RARC, robot‐assisted
radical cystectomy.
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with ileal conduits only, RARC proved not only better perioperative
outcomes than ORC, but robotic intracorporeal ileal conduits also
rendered better perioperative outcomes possible than for robotic
extracorporeal ileal conduits. They had a shorter operating time, less
blood loss and higher lymph node count, supporting the results of
Tan et al.33 In contrast, ICUD did not prove better results than ECUD
or ORC in our subgroup analysis with neobladders only, which can be
explained with lower case numbers. We perform intracorporeal
neobladders in the ‘W’‐shaped Hautmann technique, but also other
methods, such as the intracorporeal Padua neobladder, can provide
favourable long‐term results.34,35
Consequently, our results highlight a lower morbidity after
RARC, especially with intracorporeal diversion, but also underline the
importance of prospective trials comparing ORC and RARC with
ICUD. Fortunately, the iROC trial has recently been initiated and is
currently ongoing (NCT03049410).36 As another primary outcome,
we compared the ICU admission rates. Reports on ICU admissions
are highly variable, ranging between 1.3% and 38% for RARC and 7%
and 46% after ORC. Our ICU admissions were three times more
common in the ORC group (RARC 7.4% vs. ORC 20.3%), further
confirming a lower morbidity after RARC.37,38
These results were reached in a patient cohort resembling other
published series.39 However, patients treated with ORC had a me-
dian CCI of 5.5 and were not only more comorbid compared to the
RARC group, but also to most other published cohorts. Recently, two
database analyses including more than 20 000 patients only graded
12.1% patients CCI ≥ 2 and 1.7% patients CCI ≥ 3.40,41 As a conse-
quence, the proportion of patients with neobladders after ORC was
relatively low in our cohort (9.6%). In contrast, 28.4% of patients
received robotic neobladders, which is a comparably high proportion
of continent urinary diversions, especially for a robotic cohort. Pa-
tients treated with ORC had higher pT stages (55.8% vs. 37.1% ≥
pT3) and more lymph node metastases (pN+ 34.9% vs. 17.8%). Again,
these tumour stages are higher than in most other single centre se-
ries.28,37,42 Only a very few patients received neoadjuvant chemo-
therapy prior to surgery, as our department aims to avoid it due to
the current lack of predictive biomarkers. Consequently, mainly the
ORC cohort comprised many cases at high risk for complications.
Moreover, we assumed that the surgical results were impacted
by 1) a selection bias, as more advanced tumours were primarily
treated with ORC, and 2) a learning curve for RARC, as all robotic
cystectomies from the very first one conducted in our department
were included. For this reason, we performed a propensity score
matching, accounting for the differences between ORC and RARC
cohorts (age, CCI, pT‐ and pN‐stage), as well as the urinary diversion
type and surgical experience as potential confounders. The IRCC has
described significant improvements in perioperative outcomes after
30 RARC.5 We applied this threshold to our analysis and considered a
surgeon to be experienced after his or her 30th RARC and 30th ORC.
Remarkably, the differences concerning complications and ICU
admissions remained significant in the propensity score matched
analysis comparing 167 RARC with 167 ORC. Thus, one can deduce
that neither tumour‐specific aspects nor the surgeon’s experience, but
the surgical approach had a major impact on complications and ICU
admissions, which was confirmed in the multiple regression analysis. In
a similar analysis, Brassetti et al. also found the surgical approach to be
associated with ICU admissions or reoperations.37 Nevertheless,
complications were also impacted by patient‐specific factors in our
TAB L E 5 Multiple regression analysis to assess the impact of the surgical approach, urinary diversion and surgeon’s experience on
primary outcomes, accounting for patient (age, gender, BMI, CCI) and tumour characteristics (pT, pN stage)
Variable
Intraoperative
complications Minor complications Major complications ICU admissions
OR (95%CI) p‐value OR (95%CI) p‐value OR (95%CI) p‐value OR (95%CI) p‐value
Robotic approach (ref.: open) 0.41 (0.28; 0.59) <0.001 0.52 (0.34; 0.79) 0.002 0.38 (0.23; 0.61) <0.001 0.32 (0.18; 0.55) <0.001
Diversion (ref: conduit)
Neobladder ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Other ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Experienced surgeon (ref:
inexperienced)
‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Age (per 10 years) ‐ ‐ 1.25 (1.03; 1.53) 0.028 ‐ 0.789 ‐ 0.169
Female gender (ref: male) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
BMI ‐ ‐ 1.05 (1.0; 1.1) 0.039 1.11 (1.06; 1.16) <0.001 ‐ ‐
CCI ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Locally advanced tumour (ref.: ≤ pT2) ‐ ‐ ‐ 0.167 ‐ 0.787 ‐ ‐
pN+ (ref.: pN0) ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐
Note: The odds ratio (OR) with 95% confidence intervals (95%CI) is only given for significant associations.
Abbreviations: BMI, body mass index; CCI, Charlson comorbidity index; ECUD, extracorporeal urinary diversion; ICUD, intracorporeal urinary diversion;
ref, reference.
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multiple regression analysis. A higher BMI increased the risk for minor
and major complications, which has also been postulated by other
authors.43 Moreover, the patient age increased the risk for minor
complications. An increasing age has been identified as a predictor for
complications after RC elsewhere.44 No further factors had an impact
on complications and ICU admissions in the regression analyses, which
underlines the importance of the surgical approach.
Concerning the secondary outcomes, RARC had less blood loss
and transfusions, less PSMs, a higher lymph node yield and a shorter
length of stay, but a longer operating time not only in the overall, but
also the propensity score matched cohort. Correspondingly, all of these
outcomes were impacted by the surgical approach in the multiple
regression analysis. The PSM rates were not only influenced by the
surgical approach, but also by the experience of the surgeon and the
tumour stage. Faraj et al. illustrated a significant increase in PSMs with
higher pT‐stages, but in contrast Dell’Oglio could not find an associa-
tion between surgical experience and PSMs.6,28 According to our re-
sults, experienced surgeons had a higher OR of 3.06 for PSMs in the
multiple regression analysis, which is clearly counterintuitive. This
association can be related to an interaction of surgical experience with
tumour stage, as experienced surgeons operated on more advanced
tumours with higher pT stages, and the tumour stage itself had a much
higher OR of 14.4 for PSMs. However, PSMs were rare, especially in
the RARC cohort. The total lymph node count was not impacted by the
surgeon’s experience, but higher for RARC. This finding confirms the
results of other analyses, including the prospective RCT of Nix et al.
comparing 21 RARC with 20 ORC.17 The median length of stay was
shorter after RARC, but still much longer than in most other works
ranging from seven to nine days.20 This can be explained by differences
in health care systems, as the German reimbursement system covers a
longer hospital stay.45 Earlier discharge after RARC is possible from a
surgical point of view, as we have also begun discharging patients
earlier in recent years (first 100 RARC: 17 days, rest: 15 days); how-
ever, it has not been a crucial parameter for us.23 Finally, the operating
time was not only impacted by the surgical approach, but also the
diversion type, patient age, BMI, and of high importance, the surgeon’s
experience. The impact of the learning curve on perioperative and
especially functional outcomes of RARC has also been demonstrated
elsewhere.46,47 In this context, the current EAU guidelines highlight the
experience of the surgeon as a key factor for the surgical outcomes of
RARC.3 However, the diversity of associations in our multiple regres-
sion analysis also underlines the complexity of associations when
comparing ORC with RARC.
This study is not devoid of limitations. Due to its retrospective
nature, cohorts were not balanced in terms of surgeon’s experience,
patient and tumour characteristics. For this reason, we performed a
propensity score matching and multiple regression analyses and
aimed to control for the most important group differences and po-
tential confounders. Nonetheless, statistics cannot replace prospec-
tive, randomised controlled trials. Furthermore, not all surgeons
conducted both RARC and ORC and no mid‐ or long‐term follow‐up
was included to compare the oncological outcomes, which is
currently ongoing.
5 | CONCLUSIONS
RARC has not replaced ORC, mainly because of doubts about its
oncological safety and a long‐lasting learning curve. This has led to a
selection bias in most studies, which has potentially rendered it hard
to prove a superiority of the robot. In this large single‐centre cohort,
we performed a propensity score matching and multiple regression
analyses to control for differences in surgeon’s experience, patient,
tumour characteristics and type of urinary diversion between RARC
and ORC. Regardless, RARC had lower complication rates and blood
loss, less ICU admissions and transfusions, but longer operation
times. Thus, RARC appears to be superior to ORC.
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